References
- Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012; 12:592 - 605; http://dx.doi.org/10.1038/nri3251; PMID: 22828912
- Czerkinsky C, Holmgren J. Topical immunization strategies. Mucosal Immunol 2010; 3:545 - 55; http://dx.doi.org/10.1038/mi.2010.55; PMID: 20861833
- Norton EB, Lawson LB, Freytag LC, Clements JD. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 2011; 18:546 - 51; http://dx.doi.org/10.1128/CVI.00538-10; PMID: 21288994
- Eriksson AM, Schön KM, Lycke NY. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004; 173:3310 - 9; PMID: 15322194
- Lindqvist M, Nookaew I, Brinkenberg I, Samuelson E, Thörn K, Nielsen J, Harandi AM. Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology. PLoS One 2011; 6:e20448; http://dx.doi.org/10.1371/journal.pone.0020448; PMID: 21666746
- Jespers V, Harandi AM, Hinkula J, Medaglini D, Le Grand R, Stahl-Hennig C, Bogers W, El Habib R, Wegmann F, Fraser C, et al. Assessment of mucosal immunity to HIV-1. Expert Rev Vaccines 2010; 9:381 - 94; http://dx.doi.org/10.1586/erv.10.21; PMID: 20370549
- Bendelac A, Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 2002; 195:F19 - 23; http://dx.doi.org/10.1084/jem.20020073; PMID: 11877490
- Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172:1777 - 85; PMID: 14734761
- Keller SA, Schwarz K, Manolova V, von Allmen CE, Kinzler MG, Bauer M, Muntwiler S, Saudan P, Bachmann MF. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol 2010; 40:103 - 12; http://dx.doi.org/10.1002/eji.200939559; PMID: 19877013
- Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002; 8:373 - 8; http://dx.doi.org/10.1038/nm0402-373; PMID: 11927943
- Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271:348 - 50; http://dx.doi.org/10.1126/science.271.5247.348; PMID: 8553069
- Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O’Neil CP, Lee LK, Swartz MA, Hubbell JA. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25:1159 - 64; http://dx.doi.org/10.1038/nbt1332; PMID: 17873867
- Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF. Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen. J Immunol 2012; 188:3557 - 8; http://dx.doi.org/10.4049/jimmunol.1290012
- Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787 - 96; http://dx.doi.org/10.1038/nri2868; PMID: 20948547
- van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012; 2:300 - 5; http://dx.doi.org/10.1016/j.coviro.2012.01.008; PMID: 22709517
- Garg R, Shrivastava P, van Drunen Littel-van den Hurk S. The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. Expert Rev Vaccines 2012; 11:1441 - 57; http://dx.doi.org/10.1586/erv.12.117; PMID: 23252388
- Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock RE, Babiuk LA, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012; 30:5206 - 14; http://dx.doi.org/10.1016/j.vaccine.2012.06.011; PMID: 22713718
- van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012; 2:300 - 5; http://dx.doi.org/10.1016/j.coviro.2012.01.008; PMID: 22709517
- Tefit JN, Davies G, Serra V. NKT cell responses to glycolipid activation. Methods Mol Biol 2010; 626:149 - 67; http://dx.doi.org/10.1007/978-1-60761-585-9_11; PMID: 20099127